IP Verse

Altering Gene Expression In Cart Cells And Uses Thereof - EP3215166

The patent EP3215166 was granted to The Trustees OF The University OF Pennsylvania on Nov 27, 2024. The application was originally filed on Oct 15, 2015 under application number EP15855440A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3215166

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Application Number
EP15855440A
Filing Date
Oct 15, 2015
Status
Granted And Under Opposition
Mar 22, 2024
Grant Date
Nov 27, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANJan 24, 2025MEWBURN ELLISADMISSIBLE
MAIWALDJan 23, 2025MAIWALDADMISSIBLE
MARGARET DIXONOct 22, 2024MEWBURN ELLISADMISSIBLE

Patent Citations (56) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2004014645
DESCRIPTIONUS2004059285
DESCRIPTIONUS2004092907
DESCRIPTIONUS2005052630
DESCRIPTIONUS2005070841
DESCRIPTIONUS2007128708
DESCRIPTIONUS2014068797
DESCRIPTIONUS4694778
DESCRIPTIONUS5199942
DESCRIPTIONUS5350674
DESCRIPTIONUS5413923
DESCRIPTIONUS5545806
DESCRIPTIONUS5569825
DESCRIPTIONUS5585362
DESCRIPTIONUS5625126
DESCRIPTIONUS5633425
DESCRIPTIONUS5661016
DESCRIPTIONUS5814318
DESCRIPTIONUS5993434
DESCRIPTIONUS6080840
DESCRIPTIONUS6120766
DESCRIPTIONUS6181964
DESCRIPTIONUS6233482
DESCRIPTIONUS6241701
DESCRIPTIONUS6516223
DESCRIPTIONUS6567694
DESCRIPTIONUS6678556
DESCRIPTIONUS7171264
DESCRIPTIONUS7173116
DESCRIPTIONWO2013074916
DESCRIPTIONWO2014059173
DESCRIPTIONWO2014153470
DESCRIPTIONWO2015136001
DESCRIPTIONWO9633735
DESCRIPTIONWO9634096
DESCRIPTIONWO9824893
INTERNATIONAL-SEARCH-REPORTUS6143291
INTERNATIONAL-SEARCH-REPORTWO2013074916
INTERNATIONAL-SEARCH-REPORTWO2013126712
INTERNATIONAL-SEARCH-REPORTWO2014153470
INTERNATIONAL-SEARCH-REPORTWO2014165707
OPPOSITIONUS6143291
OPPOSITIONWO2013074916
OPPOSITIONWO2013126712
OPPOSITIONWO2014059173
OPPOSITIONWO2014153470
OPPOSITIONWO2014165707
OPPOSITIONWO2015121454
OPPOSITIONWO2015136001
OPPOSITIONWO2015157391
OPPOSITIONWO2015161276
OPPOSITIONWO2016069283
OPPOSITIONWO2016141357
OTHERWO2014184744
SEARCHWO2014059173
SEARCHWO2015136001

Non-Patent Literature (NPL) Citations (28) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- Michael H. Kershaw ET AL, "Gene-engineered T cells for cancer therapy", Nature Reviews Cancer, London, (20130801), vol. 13, no. 8, doi:10.1038/nrc3565, ISSN 1474-175X, pages 525 - 541, XP055543320
OPPOSITION- Alberts, Bruce; Wilson, John H.; Hunt, Tim; Johnson, Alexander, "Chapter 7 Control of Gene Expression", Alberts, Bruce; Wilson, John H.; Hunt, Tim; Johnson, Alexander, ALBERTS B. ET AL., MOLECULAR BIOLOGY OF THE CELL, NEW YORK , GARLAND SCIENCE , (20080101), pages 411 - 499, ISBN 978-0-8153-4105-5, XP009559937
OPPOSITION- Alberts, Bruce; Wilson, John H.; Hunt, Tim; Johnson, Alexander, "Chapter 8: Manipulating Proteins, DNA, and RNA", Alberts, Bruce; Wilson, John H.; Hunt, Tim; Johnson, Alexander, ALBERTS B. ET AL., MOLECULAR BIOLOGY OF THE CELL, NEW YORK , GARLAND SCIENCE , (20080101), pages 501 - 572, ISBN 978-0-8153-4105-5, XP009559946
OPPOSITION- Kindt, Thomas J.; Goldsby, Richard A.; Osborne, Barbara A., "Chapter 10: T-Cell Maturation, Activation, and Differentiation", Immunology, US, W. H. Freeman and Company, (20070101), pages 245 - 270, ISBN 978-0-7167-8590-3, XP009559948
OPPOSITION- Kindt, Thomas J.; Goldsby, Richard A.; Osborne, Barbara A., "Chapter 14: Cell-Mediated Cytotoxic Responses", Kindt, Thomas J.; Goldsby, Richard A.; Osborne, Barbara A., Thomas J. Kindt, Richard A. Goldsby, Barbara A. Osborne, Immunology, US, W. H. Freeman and Company, (20070101), pages 351 - 370, ISBN 978-0-7167-8590-3, XP009559949
OPPOSITION- MAUS MARCELA V ET AL, "Adoptive immunotherapy for cancer or viruses.", Inflammatory bowel disease., (20140109), vol. 32, ISSN 1545-3278, pages 189 - 225, XP002781210
OPPOSITION- Kalos M, June C H, "Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology", Immunity, Cell Press, AMSTERDAM, NL, AMSTERDAM, NL , (20130725), vol. 39, no. 1, doi:10.1016/j.immuni.2013.07.002, ISSN 1074-7613, pages 49 - 60, XP002734273
OPPOSITION- V Hoyos, B Savoldo, C Quintarelli, A Mahendravada, M Zhang, J Vera, H E Heslop, C M Rooney, M K Brenner, G Dotti, "Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety", Leukemia, Stockton Press, (20100601), vol. 24, no. 6, doi:10.1038/leu.2010.75, ISSN 08876924, pages 1160 - 1170, XP055185417
OPPOSITION- Dan Blat, Ehud Zigmond, Zoya Alteber, Tova Waks and Zelig Eshhar, "Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen-Specific Regulatory T Cells", Molecular Therapy, Nature Publishing Group, GB, GB , (20140501), vol. 22, no. 5, doi:10.1038/mt.2014.41, ISSN 1525-0024, pages 1018 - 1028, XP002758115
OPPOSITION- Michael H. Kershaw, Jennifer A. Westwood, Phillip K. Darcy, "Gene-engineered T cells for cancer therapy", Nature Reviews Cancer, Nature Pub. Group, vol. 13, no. 8, doi:10.1038/nrc3565, ISSN 1474175X, pages 525 - 541, XP055185130
OPPOSITION- Drappa Jörn, A K Vaishnaw, K E Sullivan, J L Chu, K B Elkon, "Fas GENE MUTATIONS IN THE CANALE -SMITH SYNDROME Fas GENE MUTATIONS IN THE CANALE-SMITH SYNDROME, AN INHERITED LYMPHOPROLIFERATIVE DISORDER ASSOCIATED WITH AUTOIMMUNITY", N Engl J Med, (19961128), vol. 335, no. 22, doi:10.1056/NEJM199611283352204, pages 1643 - 1649, XP093256888
OPPOSITION- Timothy Jansen, Betty Tyler, Joseph L Mankowski, Violette Renard Recinos, Gustavo Pradilla, Federico Legnani, John Laterra, Alessandro Olivi, B J T, V R R, G P, F L, A O Fondazione, "FasL gene knock-down therapy enhances the antiglioma immune response", Neuro-oncology, Oxford University Press, United States, United States , doi:10.1093/neuonc/nop052, pages 482 - 489, Neuro-oncology, URL: http://www.ncbi.nlm.nih.gov/pubmed/20406899, XP055215407
OPPOSITION- Sunitha Kakarla, Stephen Gottschalk, "CAR T Cells for Solid Tumors", CANCER JOURNAL, JONES AND BARTLETT PUBLISHERS, US, US , (20140101), vol. 20, no. 2, doi:10.1097/PPO.0000000000000032, ISSN 1528-9117, pages 151 - 155, XP055243488
OPPOSITION- Eleanor J. Cheadle, Gornall Hannah, Baldan Vania, Hanson Vivien, Hawkins Robert E., Gilham David E., "CAR T cells: driving the road from the laboratory to the clinic", Immunological Reviews, (20140113), vol. 257, no. 1, doi:10.1111/imr.12126, ISSN 01052896, pages 91 - 106, XP055177342
OPPOSITION- DOTTI G. ET AL., "Design and development of therapies using chimeric antigen receptor-expressing T cells", IMMUNOL. REV., (20131213), vol. 257, no. 1, doi:10.1111/imr.12131, pages 107 - 126, XP002791515
OPPOSITION- Chih-Ping Mao, Yen-Yu Lin, Chien-Fu Hung, T-C. Wu, "Immunological research using RNA interference technology", Immunology, Blackwell Scientific Publications., (20070701), vol. 121, no. 3, doi:10.1111/j.1365-2567.2007.02599.x, ISSN 00192805, pages 295 - 307, XP055046545
OPPOSITION- Hahne M., D Rimoldi, M Schröter, P Romero, M Schreier, L E French, P Schneider, T Bornand, A Fontana, D Lienard, J Cerottini, J Tschopp, " Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape", Science, (19961122), vol. 274, no. 5291, doi:10.1126/science.274.5291.1363, pages 1363 - 1366, XP093256904
OPPOSITION- A. Kunkele, Johnson A. J., Rolczynski L. S., Chang C. A., Hoglund V., Kelly-Spratt K. S., Jensen M. C., "Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD", Cancer Immunology Research, American Association for Cancer Research, US, US , (20150401), vol. 3, no. 4, doi:10.1158/2326-6066.CIR-14-0200, ISSN 2326-6066, pages 368 - 379, XP055231344
OPPOSITION- Gianpietro Dotti, Savoldo Barbara, Pule Martin, Straathof Karin C, Biagi Ettore, Yvon Eric, Vigouroux Stephane, Brenner Malcolm K, Rooney Cliona M, "Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis", (20050215), doi:10.1182/blood-2004-08-3337, XP055203016
OPPOSITION- Torikai H, Reik A, Liu P Q, Zhou Y, Zhang L, Maiti S, Huls H, Miller J C, Kebriaei P, Rabinovich B, Lee D A, Champlin R E, Bonini C, Naldini L, Rebar E J, Gregory P D, Holmes M C, Cooper L J, "A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY NLD, US, US , (20120614), vol. 119, no. 24, doi:10.1182/blood-2012-01-405365, ISSN 1528-0020, pages 5697 - 5705, XP002752739
OPPOSITION- Moa Fransson;Elena Piras;Joachim Burman;Berith Nilsson;Magnus Essand;BinFeng Lu;Robert A Harris;Peetra U Magnusson;Eva Brittebo;Angelica SI Loskog, "CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery", JOURNAL OF NEUROINFLAMMATION, BIOMED CENTRAL LTD., LONDON, GB, GB , (20120530), vol. 9, no. 1, doi:10.1186/1742-2094-9-112, ISSN 1742-2094, page 112, XP021127207
OPPOSITION- Weiming Wang, Chaobaihui Ye, Jingjing Liu, Di Zhang, Jason T. Kimata, Paul Zhou, "CCR5 Gene Disruption via Lentiviral Vectors Expressing Cas9 and Single Guided RNA Renders Cells Resistant to HIV-1 Infection", PLoS ONE, vol. 9, no. 12, doi:10.1371/journal.pone.0115987, page e115987, XP055326520
OPPOSITION- Carlos A Ramos, Gianpietro Dotti, "Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy", Expert Opinion on Biological Therapy, (20110701), vol. 11, no. 7, doi:10.1517/14712598.2011.573476, ISSN 14712598, pages 855 - 873, XP055122639
OPPOSITION- Villa-Morales María, Fernández-Piqueras José, "Targeting the Fas/FasL signaling pathway in cancer therapy", Expert Opinion on therapeutic targets, Informa Healthcare, UK, UK , (20120101), vol. 16, no. 1, doi:10.1517/14728222.2011.628937, ISSN 1472-8222, pages 85 - 101, XP093256896
OPPOSITION- Vera J F, Brenner M K, Dotti G., "Immunotherapy of Human Cancers Using Gene Modified T Lymphocytes", Current Gene Therapy, Bentham Science Publishers Ltd., NL, NL , (20091001), vol. 9, no. 5, doi:10.2174/156652309789753338, ISSN 1566-5232, pages 396 - 408, XP002683648
OPPOSITION- V. Hoyos, B. Savoldo, G. Dotti, "Genetic modification of human T lymphocytes for the treatment of hematologic malignancies", Haematologica, (20121101), vol. 97, no. 11, doi:10.3324/haematol.2012.064303, ISSN 03906078, pages 1622 - 1631, XP055122202
OPPOSITION- Choi Donghoon, Kim Tai-Gyu, Sung Young Chul, "The Past, Present, and Future of Adoptive T Cell Therapy", Immune Network, The Korean Society for Immunology, KP, KP , (20120101), vol. 12, no. 4, doi:10.4110/in.2012.12.4.139, ISSN 1598-2629, pages 139 - 147, XP093256915
SEARCH- MAUS MARCELA V ET AL, "Adoptive immunotherapy for cancer or viruses.", ANNUAL REVIEW OF IMMUNOLOGY 2014, (20140109), vol. 32, ISSN 1545-3278, pages 189 - 225, XP002781210 [I] 1-22 * page 193, paragraph 2 * * page 194, paragraph 3 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents